High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

Abstract Background Src homology region 2 domain‐containing phosphatase 2 (SHP2) is a novel target for Kirsten rat sarcoma oncogene (KRAS) mutant cancer. We retrospectively studied the significance of SHP2 in KRAS mutant non‐small cell lung cancer (NSCLC) treated with immunotherapy and its relations...

Full description

Bibliographic Details
Main Authors: Hui‐Bo Feng, Yu Chen, Zhi Xie, Jie Jiang, Yu‐Min Zhong, Wei‐Bang Guo, Wen‐Qing Yan, Zhi‐Yi Lv, Dan‐Xia Lu, Hong‐Ling Liang, Fang‐Ping Xu, Jin‐Ji Yang, Xue‐Ning Yang, Qing Zhou, Dong‐Kun Zhang, Zhou Zhang, Shao‐Kun Chuai, Heng‐Hui Zhang, Yi‐Long Wu, Xu‐Chao Zhang
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Thoracic Cancer
Subjects:
immunotherapy
KRAS
non‐small cell lung cancer
SHP2
Online Access:https://doi.org/10.1111/1759-7714.14137

Internet

https://doi.org/10.1111/1759-7714.14137

Similar Items